Neurobehavioral Manifestations
40 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Nervous System Diseases
Narrower: Agnosia 7, Anhedonia 3, Aphasia 4, Aphasia, Broca 1, Aphasia, Primary Progressive 1, Down Syndrome 5, Dysarthria 2, Hallucinations 1, Language Disorders 9, Lethargy 4, Mania 3, Memory Disorders 1, Persistent Vegetative State 2, Phantom Limb 1, Psychomotor Agitation 1, Speech Disorders 7
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| ACP-204 for hallucinations | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acupuncture for agnosia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aticaprant for anhedonia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Baclofen for psychomotor agitation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BrainGate Neural Interface System for aphasia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BrainGate Neural Interface System for aphasia, broca | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BrainGate Neural Interface System for dysarthria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Buprenorphine hydrochloride for agnosia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Chronic speech BCI for speech disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Communication Bridge™ for aphasia, primary progressive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Depression Cognitive Training + tDCS (active stimulation) for neurobehavioral manifestations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Depression Cognitive Training + tDCS (sham stimulation) for neurobehavioral manifestations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Divalproex sodium for mania | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab for down syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Escitalopram oxalate for aphasia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Escitalopram oxalate for lethargy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FLUOROETHOXYBENZOVESAMICOL F-18 for down syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine for down syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IM ketamine in dose finding and then continuation for phantom limb | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) for lethargy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) + METHYLPHENIDATE HYDROCHLORIDE for lethargy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketoprofen for agnosia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for down syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for down syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Leucovorin for language disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Levoleucovorin calcium for language disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Lithium for mania | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active) for lethargy | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MRI + Psilocybin + Risperidone for anhedonia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| N1 Implant + R1 Robot for dysarthria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Non-Specific Cognitive Training + tDCS (sham stimulation) for neurobehavioral manifestations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for agnosia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for anhedonia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®) with the Magnus Neuromodulation System for memory disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| stimulation device for persistent vegetative state | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Suzetrigine for agnosia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| the Terumo Hydropearl® microspheres device for agnosia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vagus nerve stimulation; for persistent vegetative state | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valproic acid for mania | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vasopressin for agnosia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.